Jing Jiang

Title: Innovations of Jing Jiang in Cancer Treatment

Introduction

Jing Jiang is a prominent inventor based in Yantai, China, known for his significant contributions to the field of cancer treatment. With a total of five patents to his name, Jiang has focused on developing innovative therapies that target specific cancer markers.

Latest Patents

One of Jiang's latest patents is the "Anti PD-L1 antibody and use thereof." This invention provides a PD-L1 immunosuppressant, specifically a monoclonal antibody capable of targeting PD-L1. The patent also includes nucleotides, combinations of polynucleotides, expression vectors, and pharmaceutical compositions that utilize the anti PD-L1 antibody for treating or preventing cancers. Another notable patent is the "Anti-mesothelin antibody and antibody drug conjugate thereof," which discloses an antibody drug conjugate targeting MSLN. This invention also outlines a method for creating the antibody drug conjugate and introduces a novel MSLN antibody or its functional fragments.

Career Highlights

Jing Jiang has worked with notable companies such as Remegen Ltd. and Remegen Co., Ltd. His work in these organizations has contributed to the advancement of cancer therapies and the development of innovative medical solutions.

Collaborations

Jiang has collaborated with esteemed colleagues, including Jianmin Fang and Changjiang Huang, who have played significant roles in his research and development efforts.

Conclusion

Jing Jiang's innovative work in the field of cancer treatment through his patents demonstrates his commitment to advancing medical science. His contributions are paving the way for new therapeutic options for patients battling cancer.